glp-1 weight loss overview Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response Glucagon-like peptide-1 receptor: mechanisms and

Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist

A nivel gastrointestinal, tambin se ha estudiado por su relacin con prostaglandinas y sntesis de xido ntrico en modelos de induccin de lcera, donde la hiptesis es una mayor proteccin de mucosa

It is transported into intestinal epithelial and immune cells via hPepT1, enabling intracellular anti-inflammatory effects (4)

If patients feel unsure about their current dose, or find that it isnt working as expected, they should speak to a clinician

Key Points: GI symptoms are the most common adverse effects, ranging from expected nausea and vomiting to gastroparesis and, rarely, functional obstruction Delayed gastric emptying has important airway implications and a cautious approach to airway management is warranted Biliary disease is one of the most clinically significant complications, particularly early in treatment and with rapid weight loss Pancreatitis is rare, and current evidence does not support a strong causal relationship EDKA and AKI are uncommon but important to recognize in the right context Conclusions: GLP-1 receptor agonists have transformed the management of diabetes and obesity, with clear benefits in weight loss, glycemic control, and cardiovascular outcomes